Thiophenes

Xarelto - Drug Insight, 2019-2021: Historical & Forecasted Sales Revenue - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 21, 2019
Health, Pharmaceutical, Chemical compounds, Organic compounds, Heterocyclic compounds, Anticoagulants, Chloroarenes, Lactams, Morpholines, Rivaroxaban, Thiophenes, SWOT

The "Xarelto - Drug Insight, 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Xarelto - Drug Insight, 2019" report has been added to ResearchAndMarkets.com's offering.
  • Xarelto Drug Insight, 2019 highlights the drug marketed details and the Global API Manufacturers details across the globe along with the location.
  • The report covers the Global Market Assessment of Xarelto covering the historical global sales and also provides the Xarelto sales estimation during the forecasted period (2019-2021).
  • In addition to this, the report also provides the SWOT analysis for Xarelto and emerging therapies in this space.

DSUVIA Efficacy and Safety Data to be Presented at the American Society of Anesthesiologists (ASA) Annual Conference

Retrieved on: 
Monday, October 15, 2018
Chemistry, Medicine, Health, Anesthesia, Fentanyl, Piperidines, Sufentanil, Thiophenes, Sublingual administration, Placebo-controlled study, Anesthesiologist, Comorbidity

The poster presentation will include efficacy and integrated safety results of sufentanil sublingual tablets across surgery types.

Key Points: 
  • The poster presentation will include efficacy and integrated safety results of sufentanil sublingual tablets across surgery types.
  • Included in this presentation are results from two randomized and placebo-controlled studies in post-operative patients following bunionectomy (SAP202) and abdominal surgery (SAP301).
  • Two studies were open-label and single-arm intended to evaluate sufentanil sublingual tablet 30 mcg (DSUVIA) in the emergency department (SAP302) and in older, post-operative patients, many with comorbidities (SAP303).
  • The data will be presented at the American Society of Anesthesiologists ANESTHESIOLOGY 2018 Annual Meeting, October 13-17 in San Francisco, California.

U.S. FDA Approves XARELTO® (rivaroxaban) to Reduce the Risk of Major Cardiovascular Events in Patients with Chronic Coronary Artery Disease (CAD) or Peripheral Artery Disease (PAD)

Retrieved on: 
Thursday, October 11, 2018
Anticoagulants, Chemistry, Organic chemistry, Medicine, Lactams, Chloroarenes, Morpholines, Rivaroxaban, Thiophenes, Direct Xa inhibitor, Aspirin

XARELTO is now the first and only Factor Xa inhibitor approved for patients living with these conditions.

Key Points: 
  • XARELTO is now the first and only Factor Xa inhibitor approved for patients living with these conditions.
  • "The new XARELTO vascular 2.5-mg dose, when used with aspirin, represents a true breakthrough for patients with chronic CAD and PAD."
  • Since its launch, XARELTO has been approved for a variety of indications and prescribed more than 45 million times worldwide.
  • XARELTO may cause serious side effects, including:
    Increased risk of blood clots if you stop taking XARELTO.

Real World Study Suggests Canagliflozin Does Not Increase Risk of Below-Knee Amputation in People with Type 2 Diabetes

Retrieved on: 
Sunday, June 24, 2018
Anti-diabetic drugs, Medicine, Clinical medicine, Canagliflozin, Glucosides, Johnson & Johnson, Thiophenes, Gliflozin, Anti-diabetic medication, Amputation, SGLT2, BKA

Patients," presented today at the American Diabetes Association's (ADA's) 78th Scientific Sessions at the Orange County Convention CenterConvention Center.

Key Points: 
  • Patients," presented today at the American Diabetes Association's (ADA's) 78th Scientific Sessions at the Orange County Convention CenterConvention Center.
  • This large comprehensive analysis found no increased risk of below-knee amputation with canagliflozin or any of the SGLT2is across the general T2D population or in patients with established cardiovascular disease.
  • 4-LB Canagliflozin (CANA) vs. Other Antihyperglycemic Agents on the Risk of Below-Knee Amputation (BKA) for Patients with T2DMA Real-World Analysis of >700,000 U.S.
  • In this large comprehensive analysis, neither CANA nor other SGLT2i showed an increased risk of amputation vs. non-SGLT2i.